Article Text

Download PDFPDF
Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer
  1. Andreas du Bois, PhD, MD*,
  2. Christian Marth, MD, PhD,
  3. Jacobus Pfisterer, MD, PhD*,
  4. Philipp Harter, MD*,
  5. Felix Hilpert, MD, PhD*,
  6. Alain G. Zeimet, MD, PhD and
  7. Jalid Sehouli, MD, PhD*
  1. *Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Studiengruppe, Germany; and
  2. Arbeitsgemeinschaft Gynaekologische Onkologie, Austria.
  1. Address correspondence and reprint requests to Andreas du Bois, PhD, MD, Chairman, Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte (KEM), Henricistrasse 92, Essen, Germany. E-mail: Prof.duBois{at}googlemail.com.

Abstract

Minority vote to statement A5 of the Fourth Ovarian Cancer Consensus Conference, Vancouver 2010, on behalf of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Germany plus North-Eastern Society of Gyneco-Oncology and the AGO Austria.

  • Ovarian cancer consensus conference
  • Neoadjuvant chemotherapy
  • Ovarian carcinoma

Statistics from Altmetric.com

Supplementary materials

Related Data

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.